Kardigan, Inc. Net Fee Amt
Kardigan, Inc. (KARD) had Net Fee Amt of $4.24 thousand as of 2026-06-18, per its S-1MEF filed 2026-06-17.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-17
- 2026-06-18: Net Fee Amt $4.24K.
- 2026-06-08: Net Fee Amt $45.48K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-18 | $4.24K S-1MEF · filed 2026-06-17 |
| 2026-06-08 | $45.48K S-1/A · filed 2026-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |